May 4, 2021

Laura Martínez López, PharmD. Candidate 2021, LECOM, College of Pharmacy, presented us with a feature that looks at the benefits of GLP-1 agonists and SGLT-2 inhibitors in decreasing coronary health disease in patients with type 2 diabetes. The results with either product were very positive. So how do you make a choice? A1c and weight may be a deciding factor, as will the use of insulin. However, there may be one good reason to chose SGLT-2 inhibitors, and that could be the effect these drugs have on patients with chronic kidney disease.

Check out Laura’s Laterpay article and the newsflash from our publisher Steve Freed.

 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief